Dyslipidemia Prevalence, Perception, Treatment, and Awareness in the Tunisian Population
ATERASurvey
1 other identifier
observational
13,610
1 country
1
Brief Summary
ATERA Survey is a national cross sectional observational study, aiming to determine the prevalence of dyslipidemia and other conventional risk factors for CHD (Coronary Heart Disease), the relationship between environmental and lifestyle factors with dyslipidemia, the perception and the knowledge of cardiovascular risk factors by the population, and above all, to strengthen the national strategy for primary and secondary prevention against coronary heart disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2016
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 4, 2016
CompletedFirst Submitted
Initial submission to the registry
January 8, 2019
CompletedFirst Posted
Study publicly available on registry
January 10, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
August 31, 2019
CompletedJanuary 22, 2020
January 1, 2020
3.7 years
January 8, 2019
January 17, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Prevalence of dyslipidemia
Frequency of subjects with hypercholesterolemia and/or hypertriglyceridaemia
At inclusion
Secondary Outcomes (1)
Prevalence of cardiovascular associated risk factors
At inclusion
Other Outcomes (1)
Dietary assessment
Up to 1 month
Eligibility Criteria
All subjects aged between 25 and 75 years who accept to participate at the study
You may qualify if:
- All subjects
You may not qualify if:
- Prescribed treatment for cancer
- Organ transplantation
- Known auto-immune disease
- Severe liver disease
- Chronic renal failure
- Pregnant women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Association Tunisienne d'Etude & de Recherche sur l'Athéroscléroselead
- Biochimie Clinique LR99ES11collaborator
- Department of Biochemistry, La Rabta Hospital, Tunisia.collaborator
- Ministry of Health, Tunisiacollaborator
- Ministry of Interior, Tunisiacollaborator
- Direction des Soins de Santé de Basecollaborator
- National Institute of Statisticscollaborator
- National Institute of Public Health of Tunisiacollaborator
- Dacima Consultingcollaborator
Study Sites (1)
ATERA : Association Tunisienne d'Etude & de Recherche sur l'Athérosclérose
Tunis, 1007, Tunisia
Biospecimen
Serum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Amani Kallel, PhD
Association Tunisienne d'Etude & de Recherche sur l'Athérosclérose
- STUDY CHAIR
Riadh Jemaa, PhD
Association Tunisienne d'Etude & de Recherche sur l'Athérosclérose
Study Design
- Study Type
- observational
- Observational Model
- FAMILY BASED
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 1 Day
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 8, 2019
First Posted
January 10, 2019
Study Start
January 4, 2016
Primary Completion
August 31, 2019
Study Completion
August 31, 2019
Last Updated
January 22, 2020
Record last verified: 2020-01